Symbols / ONCSQ $0.00 +0.00% OncoSec Medical Incorporated

Healthcare • Biotechnology • United States • PNK
ONCSQ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 596.00
Enterprise Value 4.78M
Income -29.39M
Sales —
FCF (ttm) -16.43M
Book/sh -1.85
Cash/sh 1.24
Employees 40
Insider 10d —
IPO Apr 07, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B -0.00
P/C —
EV/EBITDA -0.15
EV/Sales —
Quick Ratio 0.51
Current Ratio 0.89
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -149.10
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2022-12-15
Earnings (prior) 2022-12-15
ROA -92.84%
ROE -4.10%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 5.96M
Shs Float 2.51M
Insider Own 0.00%
Instit Own 0.00%
Short Float 3.70%
Short Ratio 0.34
Short Interest 192.06K
52W High 0.00
vs 52W High 0.00%
52W Low 0.00
vs 52W Low 900.00%
Beta 16.07
Impl. Vol. —
Rel Volume —
Avg Volume 0.00
Volume 123.29K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-49.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
News
RSS: Latest ONCSQ news

No recent news from Yahoo. Try the RSS feed for latest ONCSQ news.

Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-07-31 2021-07-31
Total Revenue
0.00
0.00
Operating Revenue
0.00
0.00
Operating Expense
37.01
-23.50%
48.38
Research And Development
25.82
-24.27%
34.10
Selling General And Administration
11.19
-21.65%
14.28
General And Administrative Expense
11.19
-21.65%
14.28
Other Gand A
11.19
-21.65%
14.28
Total Expenses
37.01
-23.50%
48.38
Operating Income
-37.01
+23.50%
-48.38
Total Operating Income As Reported
-37.01
+23.50%
-48.38
EBITDA
-36.43
+21.64%
-46.49
Normalized EBITDA
-35.92
+24.07%
-47.30
Reconciled Depreciation
1.07
-1.10%
1.08
EBIT
-37.49
+21.17%
-47.56
Total Unusual Items
-0.51
-162.40%
0.82
Total Unusual Items Excluding Goodwill
-0.51
-162.40%
0.82
Special Income Charges
0.00
-100.00%
0.96
Other Special Charges
—
-0.96
Net Income
-34.18
+24.33%
-45.17
Pretax Income
-37.51
+21.16%
-47.58
Net Non Operating Interest Income Expense
-0.02
-31.96%
-0.02
Interest Expense Non Operating
0.02
+31.96%
0.02
Net Interest Income
-0.02
-31.96%
-0.02
Interest Expense
0.02
+31.96%
0.02
Other Income Expense
-0.48
-158.92%
0.82
Other Non Operating Income Expenses
0.03
+4199.01%
-0.00
Gain On Sale Of Security
-0.51
-253.72%
-0.14
Tax Provision
-3.33
-38.22%
-2.41
Tax Rate For Calcs
0.00
+75.35%
0.00
Tax Effect Of Unusual Items
-0.05
-209.42%
0.04
Net Income Including Noncontrolling Interests
-34.18
+24.33%
-45.17
Net Income From Continuing Operation Net Minority Interest
-34.18
+24.33%
-45.17
Net Income From Continuing And Discontinued Operation
-34.18
+24.33%
-45.17
Net Income Continuous Operations
-34.18
+24.33%
-45.17
Normalized Income
-33.72
+26.62%
-45.94
Net Income Common Stockholders
-34.18
+24.33%
-45.17
Diluted EPS
-19.14
+36.50%
-30.14
Basic EPS
-19.14
+36.50%
-30.14
Basic Average Shares
1.79
+19.45%
1.50
Diluted Average Shares
1.79
+19.45%
1.50
Diluted NI Availto Com Stockholders
-34.18
+24.33%
-45.17
Line Item Trend 2022-07-31 2021-07-31
Total Assets
21.88
-61.12%
56.28
Current Assets
15.23
-69.03%
49.18
Cash Cash Equivalents And Short Term Investments
12.30
-73.23%
45.95
Cash And Cash Equivalents
12.30
-73.23%
45.95
Prepaid Assets
2.93
-9.15%
3.23
Total Non Current Assets
6.65
-6.35%
7.10
Net PPE
5.64
-11.46%
6.37
Gross PPE
7.20
-7.01%
7.74
Accumulated Depreciation
-1.55
-13.71%
-1.37
Properties
0.00
0.00
Machinery Furniture Equipment
0.11
+0.00%
0.11
Construction In Progress
0.45
+90.42%
0.23
Other Properties
6.61
-10.25%
7.37
Leases
0.03
+0.00%
0.03
Goodwill And Other Intangible Assets
0.38
-15.58%
0.45
Other Intangible Assets
0.38
-15.58%
0.45
Other Non Current Assets
0.62
+127.86%
0.27
Total Liabilities Net Minority Interest
15.76
-13.41%
18.20
Current Liabilities
6.63
-16.69%
7.96
Payables And Accrued Expenses
4.53
-23.04%
5.88
Payables
0.01
-19.11%
0.01
Other Payable
0.01
-19.11%
0.01
Current Accrued Expenses
4.52
-23.04%
5.87
Pensionand Other Post Retirement Benefit Plans Current
0.06
0.00
Current Debt And Capital Lease Obligation
2.05
-1.51%
2.08
Current Debt
0.94
-24.11%
1.23
Other Current Borrowings
—
1.23
Current Capital Lease Obligation
1.11
+31.47%
0.85
Total Non Current Liabilities Net Minority Interest
9.13
-10.86%
10.24
Long Term Debt And Capital Lease Obligation
4.13
-21.22%
5.24
Long Term Capital Lease Obligation
4.13
-21.22%
5.24
Other Non Current Liabilities
5.00
+0.00%
5.00
Stockholders Equity
6.12
-83.93%
38.08
Common Stock Equity
6.12
-83.93%
38.08
Capital Stock
0.00
+0.56%
0.00
Common Stock
0.00
+0.56%
0.00
Share Issued
1.79
+0.58%
1.78
Ordinary Shares Number
1.79
+0.58%
1.78
Additional Paid In Capital
288.23
+0.66%
286.34
Retained Earnings
-285.96
-13.58%
-251.78
Gains Losses Not Affecting Retained Earnings
0.25
+412.49%
-0.08
Total Equity Gross Minority Interest
6.12
-83.93%
38.08
Total Capitalization
6.12
-83.93%
38.08
Working Capital
8.60
-79.14%
41.22
Invested Capital
7.05
-82.05%
39.31
Total Debt
6.17
-15.62%
7.32
Capital Lease Obligations
5.24
-13.90%
6.08
Net Tangible Assets
5.74
-84.75%
37.63
Tangible Book Value
5.74
-84.75%
37.63
Current Notes Payable
0.94
-24.11%
1.23
Other Equity Interest
3.59
+0.00%
3.59
Line Item Trend 2022-07-31 2021-07-31
Operating Cash Flow
-32.14
+23.10%
-41.79
Cash Flow From Continuing Operating Activities
-32.14
+23.10%
-41.79
Net Income From Continuing Operations
-34.18
+24.33%
-45.17
Depreciation Amortization Depletion
1.07
-1.10%
1.08
Depreciation
1.07
-1.10%
1.08
Depreciation And Amortization
1.07
-1.10%
1.08
Other Non Cash Items
0.04
-90.91%
0.47
Stock Based Compensation
1.65
-67.89%
5.14
Operating Gains Losses
0.51
+162.40%
-0.82
Net Foreign Currency Exchange Gain Loss
0.51
+253.72%
0.14
Change In Working Capital
-1.23
+50.77%
-2.49
Change In Prepaid Assets
1.32
+115.77%
0.61
Change In Payables And Accrued Expense
-1.38
+46.07%
-2.56
Change In Other Working Capital
0.06
+58.53%
0.04
Change In Other Current Assets
-0.38
-862.39%
0.05
Change In Other Current Liabilities
-0.85
-34.22%
-0.63
Investing Cash Flow
-0.24
+69.38%
-0.80
Cash Flow From Continuing Investing Activities
-0.24
+69.38%
-0.80
Net PPE Purchase And Sale
-0.24
+19.61%
-0.30
Purchase Of PPE
-0.24
+19.61%
-0.30
Capital Expenditure
-0.24
+69.38%
-0.80
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.49
Purchase Of Intangibles
0.00
+100.00%
-0.49
Financing Cash Flow
-1.16
-101.70%
68.21
Cash Flow From Continuing Financing Activities
-1.16
-101.70%
68.21
Net Issuance Payments Of Debt
-1.33
-114.11%
-0.62
Issuance Of Debt
—
0.00
Repayment Of Debt
-1.33
-114.11%
-0.62
Long Term Debt Issuance
—
0.00
Long Term Debt Payments
—
-0.62
Net Long Term Debt Issuance
—
0.00
Short Term Debt Payments
-1.33
-114.11%
-0.62
Net Short Term Debt Issuance
-1.33
-114.11%
-0.62
Net Common Stock Issuance
0.00
-100.00%
62.84
Proceeds From Stock Option Exercised
0.20
-96.23%
5.44
Net Other Financing Charges
-0.04
-107.49%
0.55
Changes In Cash
-33.54
-230.96%
25.62
Effect Of Exchange Rate Changes
-0.11
-472.90%
-0.02
Beginning Cash Position
45.95
+125.76%
20.35
End Cash Position
12.30
-73.23%
45.95
Free Cash Flow
-32.38
+23.97%
-42.59
Interest Paid Supplemental Data
0.02
+103.12%
0.01
Income Tax Paid Supplemental Data
0.00
-40.52%
0.00
Common Stock Issuance
0.00
-100.00%
62.84
Issuance Of Capital Stock
0.00
-100.00%
62.84
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category